UK's National Institute for Clinical Excellence (NICE) Final Appraisal Determination (FAD) Confirms Positive Recommendation for ThromboGenics NV' JETREA&#0174 for Treatment of Vitreomacular Traction and Macular Hole

Published: Sep 03, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LEUVEN, Belgium, September 2, 2013 /PRNewswire/ --

Metamorphopsia confirmed as a severe and distressing symptom deserving immediate attention and early treatment with reimbursement

• NICE FAD recommending reimbursement of JETREA for treatment of VMT patients, from early stage to late-stage (full thickness macular hole (FTMH) < 400 microns), when severe and distressing symptoms; patients with ERMs are excluded.

Help employers find you! Check out all the jobs and post your resume.

Back to news